News

The RX-04 program is focused on using a novel binding site within the ribosome to develop new classes of antibiotics to treat some of the multi-drug resistant Gram-positive

The company sales for the twelve months of 2011 are approximately $21,000,000, which is an increase of 425%, compared to all of 2010 sales of $4,000,000, the company

The grant was obtained through Bundesministeriumfur Bildung und Forschung or German Federal Ministry for Education and Research (BMBF) ) Leading Edge Cluster program. The goal of the funded

The multicenter randomized double-blind placebo-controlled Phase III studies evaluated Suvorexant compared to placebo in adult patients aged 18 years and older. In the trials, the primary endpoint was

The company plans to launch the product in Austria after completion of the national pricing and reimbursement process. Almirall, GW’s marketing partner, will market Sativex in Austria. In

The recall of Ofirmev lot number V005710 was initiated due to the presence of an unidentified, visible particle in one vial of this lot during routine stability testing.

The agreement includes milestones, upfront license fees and royalties payable to both the companies. The terms of the agreement are consistent with BioLineRx’s standard in-license agreements. BL-8030 is

As per the agreement, Eurofins STA will gain non-exclusive rights to a number of GTG patents relating to its non-coding DNA technology. The precise commercial terms of the

The randomized study is designed to test whether remote health monitoring is feasible in patients with moderate-severe COPD, improves treatment adherence, symptoms, activity level and quality of life.